

## ANIMAL AND CELL MODELS FOR DETECTION AND CHARACTERISATION OF LEUKEMIC STEM CELLS GROUP

 **Publications: 12**

 **Impact Factor: 47.99**

 **QI: 4**



### PUBLICATIONS

- Albendea MAC. Positron emission tomography in primary brain lymphoma: Diagnostic and prognostic significance. *Med Clin.* 2015;144(11):501-2. Editorial Material. IF: 1.267; Q2.
- Antelo ML, de las Heras N, Porras JRG, Kerguelen A, Raya JM. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide. *Expert Rev Hematol.* 2015;8(6):819-35. Review. IF: 2.439; Q3.
- Bernal T, Martínez-Cambor P, Sánchez-García J, de Paz R, Luno E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Canizo C, Tormo M, Bargay J, Valcarcel D, Brunet S, Benlloch L, Sanz G. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. *Leukemia.* 2015;29(9):1875-81. Article. IF: 12.104; D1.
- Bravo M, Nicolini F, Starowicz K, Barroso S, Calés C, Aguilera A, Vidal M. Polycomb RING1A-and RING1B-dependent histone H2A monoubiquitylation at pericentromeric regions promotes S-phase progression. *J Cell Sci.* 2015;128(19):3660-71. Article. IF: 4.706; Q2.
- Casado LF, García-Gutiérrez JV, Massague I, Giraldo P, Pérez-Encinas M, de Paz R, Martínez-López J, Bautista G, Osorio S, Requena MJ, Palomera L, Penarrubia MJ, Calle C, Hernández-Rivas JA, Burgaleta C, Maestro B, García-Ormena N, Steegmann JL. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. *Cancer Med-Us.* 2015;4(7):995-1002. Article. IF: 2.915; Q3.
- Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Álvarez-Larran A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. *Ann Hematol.* 2015;94(6):911-8. Article. IF: 3.022; Q2.
- Montalbán-Bravo G, Fuentes AEK, Albendea MAC, Román MA, Salces MM, Jiménez-Yuste V. Light-chain amyloidosis presenting as a change in bleeding phenotype in a patient with mild haemophilia A. *Haemophilia.* 2015;21(1):E92-4. Letter. IF: 2.673; Q2.
- Remacha AF, Arrizabalaga B, Villegas A, Durán MS, Herminos L, de Paz R, García M, Campelo MD, Sanz G. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. *Ann Hematol.* 2015;94(5):779-87. Article. IF: 3.022; Q2.
- Saumell S, Sole F, Arenillas L, Montoro J, Valcarcel D, Pedro C, Sanzo C, Luno E, Giménez T, Arnan M, Pomares H, de Paz R, Arrizabalaga B, Jerez A, Martínez AB, Sánchez-Castro J, Rodríguez-Gambarte JD, Raya JM, Ríos E, Rodríguez-Rivera M, Espinet B, Florensa L. Trisomy 8, a Cytogenetic abnormality in myelodysplastic syndromes, is constitutional or not? *Plos One.* 2015;10(6):-e0129375. Article. IF: 3.057; Q1.
- Valcarcel D, Sanz G, Ortega M, Nomdedeu B, Luno E, Díez-Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, Andréu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy B, Ramos F, Bargay J, González B, Brunet S, Muñoz JA, Gómez V, Bailén A, Sánchez J, Merchán B, del Canizo C, Vallespii T. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-I risk categories: a population-based study. *Lancet Haematol.* 2015;2(6):E260-6. Article. IF: 4.889; Q1.
- Vallejo C, Montesinos P, Polo M, Cuevas B, Morado M, Rosell A, Xicoy B, Díez JL, Salamero O, Cedillo A, Martínez P, Rayón C. Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. *Ann Hematol.* 2015;94(6):947-54. Article. IF: 3.022; Q2.
- Villarejo A, Molina-Ortiz P, Montenegro Y, Moreno-Bueno G, Morales S, Santos V, Gridley T, Pérez-Moreno MA, Peinado H, Portillo F, Calés C, Cano A. Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors. *Carcinogenesis.* 2015;36(5):585-97. Article. IF: 4.874; Q1.